Ipsen Deepens Ties with Exelixis to Enhance Treatment for Neuroendocrine Tumors

Tuesday, 2 July 2024, 07:34
The collaboration between Ipsen and Exelixis intensifies as they enhance the use of Cabometyx in treating advanced neuroendocrine tumors. This strategic move aims to provide better therapeutic options for patients dealing with this complex medical condition. The expanded partnership signifies a joint commitment to advancing treatment modalities in the field of neuroendocrine oncology.
Seeking Alpha
Ipsen Deepens Ties with Exelixis to Enhance Treatment for Neuroendocrine Tumors

Ipsen Expands Collaboration with Exelixis

Ipsen and Exelixis have strengthened their collaboration to enhance the treatment of advanced neuroendocrine tumors, focusing on the use of Cabometyx.

Strategic Move for Better Therapeutic Options

  • Joint Commitment: Ipsen and Exelixis aim to improve treatment modalities for patients.
  • Specialized Focus: The partnership targets advanced neuroendocrine conditions.

Their shared goal is to advance the field of neuroendocrine oncology.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe